Skip to main navigation Skip to search Skip to main content

Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling

  • Rick Admiraal
  • , Charlotte van Kesteren
  • , Jaap Jan Boelens
  • , Robbert G M Bredius
  • , Dick Tibboel
  • , Catherijne A J Knibbe

Research output: Contribution to journalArticlepeer-review

Abstract

When growing up, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of drugs change, which may alter the effect of drugs. To ensure optimal drug efficacy and safety in paediatric care, PK and PD relationships of drugs need to be explored in children. This article presents an outline on performing a population PK/PD study and translating these results into rational dosing regimens, with the development and prospective evaluation of PK/PD derived evidence-based dosing regimen being discussed. Examples on amikacin, morphine and busulfan are provided, showing how PK(/PD) modelling not only led to optimization and individualization in paediatric clinical care for the specific drugs but also to insight in maturation of organ systems involved. It is shown that the latter results can subsequently be used as a basis for dosing of other drugs eliminated through the same pathway. Ultimately, these efforts should lead to predictable drug efficacy and safety across all age groups.

Original languageEnglish
Pages (from-to)267-72
Number of pages6
JournalArchives of disease in childhood
Volume99
Issue number3
DOIs
Publication statusPublished - Mar 2014
Externally publishedYes

Keywords

  • Alkylating Agents/administration & dosage
  • Amikacin/administration & dosage
  • Analgesics, Opioid/administration & dosage
  • Anti-Bacterial Agents/pharmacokinetics
  • Busulfan/administration & dosage
  • Child
  • Dose-Response Relationship, Drug
  • Evidence-Based Medicine
  • Humans
  • Models, Biological
  • Morphine/administration & dosage
  • Pediatrics

Fingerprint

Dive into the research topics of 'Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling'. Together they form a unique fingerprint.

Cite this